Skip to content

US · PFE · DRUG MANUFACTURERS - GENERAL

Pfizer Inc. (PFE) intrinsic value and stock valuation

$27.40as of 2026-11-21 · Mkt cap 147.1B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pfizer Inc. DCF and intrinsic value

InvestorsCraft values PFE with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from PFE’s statements →

Pfizer Inc. Graham Number

Graham Number: $21.67d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General New York City, NY 10001-2192 pfizer.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$62.6B+8.5% 5y CAGRd
20112025
Net income
$7.77B-3.2% 5y CAGRd
20112025
Free cash flow
$9.08B-4.8% 5y CAGRd
20112025
Total equity
$86.8B+6.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$62.6B$63.6B$59.6B$100.3B$81.3B
Operating income$15.4B$16.5B$5.29B$37.5B$20.8B
Net income$7.77B$8.02B$2.13B$31.4B$22.1B
EPSd$1.37M$1.41M$373.6K$5.47M$3.88M
Operating cash flow$11.7B$12.7B$8.7B$29.3B$32.6B
Capital expenditure-$-2.63B-$-2.91B-$-3.91B-$-3.24B-$-2.71B
Free cash flow$9.08B$9.84B$4.79B$26B$29.9B
Total assets$208.2B$213.4B$226.5B$197.2B$181.5B
Total debt$67.4B$67B$70.8B$34.9B$37B
Net debt$66.3B$66B$68B$34.4B$35.1B
Total equity$86.8B$88.5B$89.3B$95.9B$77.5B
Cash and short-term investments$13.6B$20.5B$12.7B$22.7B$31.1B
Income statement
20252024202320222021
Revenue$62.6B$63.6B$59.6B$100.3B$81.3B
Cost of revenue$18.6B$21.8B$29.2B$38.2B$34.4B
Gross profit$44B$41.8B$30.3B$62.1B$46.9B
Research and development expenses$12B$10.7B$10.6B$11.4B$13.8B
Selling, general and administrative expenses$13.3B$14.7B$14.5B$13.1B$12.3B
Other expenses$3.26B-$-105M$0.00$0.00$0.00
Operating expenses$28.6B$25.4B$25B$24.5B$26.1B
Cost and expenses$47.1B$47.1B$54.3B$62.8B$60.5B
Interest income$603M$545M$1.62B$251M$36M
Interest expense$2.67B$3.09B$2.21B$1.24B$1.29B
Depreciation and amortization$4.91B$7.01B$6.29B$5.06B$5.19B
Ebitda$15.1B$18.1B$9.56B$41B$30.8B
Operating income$15.4B$16.5B$5.29B$37.5B$20.8B
Total other income/expenses, net-$-7.92B-$-8.46B-$-4.23B-$-2.82B$3.52B
Income before tax$7.52B$8.02B$1.06B$34.7B$24.3B
Income tax expense-$-266M-$-28M-$-1.11B$3.33B$1.85B
Net income$7.77B$8.02B$2.13B$31.4B$22.1B
Weighted average shares outstanding$5.68B$5.66B$5.64B$5.61B$5.6B
Weighted average diluted shares outstanding$5.69B$5.7B$5.71B$5.73B$5.71B
Balance sheet
20252024202320222021
Cash and short-term investments$13.6B$20.5B$12.7B$22.7B$31.1B
Net receivables$15.8B$14.8B$15.5B$14.5B$15.7B
Inventory$10.7B$10.9B$10.2B$8.98B$9.06B
Total current assets$42.9B$50.4B$43.3B$51.3B$59.7B
Property, plant and equipment, net$21.5B$18.4B$18.9B$16.3B$14.9B
Goodwill and intangible assets$125B$123.9B$132.7B$94.7B$74.4B
Long-term investments$1.74B$2.23B$15.4B$15.1B$21.5B
Total non-current assets$165.3B$163B$183.2B$145.9B$121.8B
Total assets$208.2B$213.4B$226.5B$197.2B$181.5B
Accounts payable$5.24B$5.63B$6.71B$6.81B$5.58B
Short-term debt$3.48B$7.3B$10.3B$2.93B$2.24B
Deferred revenue$784M$1.51B$2.7B$2.52B$3.07B
Total current liabilities$37B$43B$47.8B$42.1B$42.7B
Long-term debt$63.9B$59.7B$60.5B$31.9B$34.8B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$84.4B$81.9B$89.4B$59.2B$61.3B
Capital lease obligations$2.29B$2.64B$0.00$0.00$0.00
Total liabilities$121.4B$124.9B$137.2B$101.3B$104B
Common stock$481M$480M$478M$476M$473M
Retained earnings$114.6B$116.7B$118.4B$125.7B$103.4B
Accumulated other comprehensive income (loss)-$-8.07B-$-7.84B-$-7.96B-$-8.3B-$-5.9B
Total equity$86.8B$88.5B$89.3B$95.9B$77.5B
Total investments$14.2B$21.7B$25.2B$37.4B$50.7B
Total debt$67.4B$67B$70.8B$34.9B$37B
Net debt$66.3B$66B$68B$34.4B$35.1B
Cash flow statement
20252024202320222021
Net income$7.75B$8.05B$2.17B$31.4B$22.5B
Depreciation and amortization$6.59B$7.01B$6.29B$5.06B$5.19B
Stock-based compensation$0.00$877M$525M$872M$1.18B
Change in working capital-$-5.35B-$-3.07B-$-2.17B-$-4.46B$12.8B
Accounts receivable-$-263M-$-109M$347M$261M-$-3.81B
Inventory$561M-$-854M$6.2B$592M-$-1.13B
Accounts payable-$-469M-$-1.02B-$-300M$1.19B$1.24B
Net cash provided by operating activities$11.7B$12.7B$8.7B$29.3B$32.6B
Investments in property, plant and equipment-$-2.63B-$-2.91B-$-3.91B-$-3.24B-$-2.71B
Acquisitions, net-$-6.93B$7.04B-$-43.43B-$-23B-$-12M
Net cash used for investing activities-$-1.35B$2.65B-$-32.28B-$-15.78B-$-22.55B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00-$-2B$0.00
Dividends paid-$-9.77B-$-9.51B-$-9.25B-$-8.98B-$-8.73B
Net cash used for financing activities-$-10.3B-$-17.14B$26.1B-$-14.83B-$-9.82B
Net change in cash$99M-$-1.81B$2.45B-$-1.52B$158M
Cash at end of period$1.14B$1.11B$2.92B$468M$1.98B
Operating cash flow$11.7B$12.7B$8.7B$29.3B$32.6B
Capital expenditure-$-2.63B-$-2.91B-$-3.91B-$-3.24B-$-2.71B
Free cash flow$9.08B$9.84B$4.79B$26B$29.9B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pfizer Inc.

        Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

        CEO
        Albert Bourla
        Employees
        75K
        Beta
        0.31

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Pfizer Inc. (PFE)?

        Pfizer Inc. (PFE) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PFE undervalued?

        PFE trades at a price of $27.40 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.